Abstract
Purpose. To evaluate (1) allometric scaling of systemic clearance (CL)using unbound drug concentration, (2) the potential usage of brainweight (BRW) correction in allometric scaling of both CL and oralclearance (CL/F).
Methods. Human clearance was predicted allometrically (CLu = a ·Wbiv) using unbound plasma concentration for eight Parke-Daviscompounds and 29 drugs from literature sources. When the exponent bivwas higher than 0.85, BRW was incorporated into the allometricrelationship (CLu*BRW = a · Wbiv). This approach was also applied tothe prediction of CLu/F for 10 Parke-Davis compounds. Human oralt1/2, Cmax, AUC, and bioavailability were estimated based onallometrically predicted pharmacokinetic (PK) parameters.
Results. Human CL and CL/F were more accurately estimated usingunbound drug concentration and the prediction was further improvedwhen BRW was incorporated into the allometric relationship. ForParke-Davis compounds, the predicted human CL and CL/F werewithin 50-200% and 50-220% of the actual values, respectively. Theestimated human oral t1/2, Cmax, and AUC were within 82-220%,56-240%, and 73-190% of the actual values for all 7 compounds,suggesting that human oral PK parameters of those drugs could bereasonably predicted from animal data.
Conclusions. Results from the retrospective analysis indicate thatallometric scaling of free concentration could be applied to orallyadministered drugs to gain knowledge of drug disposition in man, and to helpdecision-making at early stages of drug development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmcokin. Biopharm. 2, 165–176 (1980).
H. Boxenbaum. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. 15:1071–1121 (1984).
H. Boxenbaum, Time concepts in physics, biology, and pharmacokinetics. J. Pharm. Sci. 75:1053–1062 (1986).
H. Boxenbaum and C. Dilea. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. 35: 957–966 (1995).
M. Rose Feng, J. Loo, and J. Wright. Disposition of the antipsychotic CI-1007 in rat, monkey, dog, and human CYP2D6 extensive metabolizers: species comparison and allometric scaling. Drug Metab. Dispos. 10:982–988 (1998).
M. R. Feng, D. Rossi, C. Strenkoski, A. Black, P. DeHart, M. Lovdahl, and William McNally. Disposition of cobalt mesoporphyrin in mice, rat, monkey, and dog. Xenobiotica 4:413–426 (1998).
G. Robbie and W. L. Chiou. Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm. Res. 10: 1630–1636 (1998).
I. Mahmood, and J. Balian. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895 (1996)
I. Mahmood. Interspecies scaling: predicting clearance of anticancer drugs in humans. Eur. J. Drug Metab. Pharmacokin. 3: 275–278 (1996).
G. Robbie and W. L. Chiou. Elucidation of human amphotericin Bpharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm. Res. 10: 1630–1636 (1998).
W. L. Chiou, G. Robbie, S. Chung, T. Wu, and C. Ma. Correlation of plasma clearance of 54 extensively metabolized drugs between human and rats: mean allometric coefficient of 0.66. Pharm. Res. 9:1474–1479 (1998).
Sanford Bolton. In James Swarbrick (ed), Pharmaceutical statistics: practical and clinical applications. Marcel Dekker Inc. New York. 1997, p. 17.
W. G. Richter, P. Heizmann, J. Meyer, V. Starke, and T. Lave. Animal Pharmacokinetics and interspecies scaling of Ro 25-6833 and related (Lactamylvinyl)cephalosporins. J. Pharm. Sci. 4: 496–500 (1998).
H. Mataushita, H. Suzuki, Y. Sugiyama, etc. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J. Pharmacobio-Dyn. 13 602–611 (1990).
J. Mordenti. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J. Pharm. Sci. 10:1097–1099 (1985).
A. Hutchaleelaha, H. Chow, and M. Mayerson. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J. Pharm. Pharmacol. 49:178–183 (1997).
T. Lave, S. Duoin, C. Schmitt, R. C. Chou, D. Jaeck, and P. Coassolo. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. 5:584–585 (1997).
Y. Tsunekawa, T. Hasegawa, M. Nadai, K. Takagi, and T. Nabeshima. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J. Pharm. Pharmacol. 44:594–599 (1992).
P. Hinderling, C. Dilea, T. Koziol, and G. Millington. Comparative kinetics of sematilide in four species. Drug Metab. Dispos. 4:662–669 (1993).
M. Widman, L. B. Nilsson, B. Bryske, and J. Lundström. Disposition of Remoxipride in different species. Arzneim-Forsch./Drug Res. 43:287–297 (1993).
H. M. Siefert, D. Maruhn, W. Maul, D. Forster, and W. Ritter. Pharmacokinetics of ciprofloxacin. Arzneim-Forsch./Drug Res. 36:1496–1502 (1986).
J. Nouws, D. Mevius, T. Vree, A. Baars, and J. Larenses. Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Quart. 3:156–163 (1988).
In J. Hardman and L. Limbird (eds). Goodman & Gilman's: The Pharmacological Basis for Therapeutics. McGraw-Hill, New York. 1997, p. 1729.
K, Nakagawa, M. Kouama, H. Matsui, C. Ikeda, K. Yano, N. Nakatsuru, K. Yoshinaga, and T. Noguchi. Pharmacokinetics of Cefpiramide (SM-1652) in humans. Antimicrob. Agents Chemother. 2:221–225 (1984).
T. Lave, S. P. Coassolo, and B. Reigner. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro–in vivo correlation Clin. Pharmacokin.. 3:211–231 (1999).
Pahlman, M. Edholm, S. Kankaanranta and M.-L. Odell. Pharmacokinetics of Susalimod, a highly biliary-excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm. Pharmacol. Commun. 4:493–498 (1998).
J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 10:1008–1020 (1995).
W. L. Chiou and A. Barve. Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm. Res. 11:1792–1795 (1998).
S. Yee. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man–fact or myth. Pharm. Res. 14:763–766 (1997).
R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic micosomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 11:1350–1359 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feng, M.R., Lou, X., Brown, R.R. et al. Allometric Pharmacokinetic Scaling: Towards the Prediction of Human Oral Pharmacokinetics. Pharm Res 17, 410–418 (2000). https://doi.org/10.1023/A:1007520818956
Issue Date:
DOI: https://doi.org/10.1023/A:1007520818956